These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38697405)

  • 1. Reporting of health equity considerations in vaccine trials for COVID-19: author's reply.
    Kou R; Mbuagbaw L
    J Clin Epidemiol; 2024 Jul; 171():111374. PubMed ID: 38697405
    [No Abstract]   [Full Text] [Related]  

  • 2. Reporting of health equity considerations in vaccine trials for COVID-19: comment on Kou et al.
    Daungsupawong H; Wiwanitkit V
    J Clin Epidemiol; 2024 Jul; 171():111329. PubMed ID: 38521365
    [No Abstract]   [Full Text] [Related]  

  • 3. Reporting of health equity considerations in vaccine trials for COVID-19: a methodological review.
    Kou R; Sadafi SL; Principato R; Anderson LN; Brignardello-Petersen R; Mbuagbaw L
    J Clin Epidemiol; 2024 May; 169():111315. PubMed ID: 38447854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.
    Rid A; Lipsitch M; Miller FG
    JAMA; 2021 Jan; 325(3):219-220. PubMed ID: 33315080
    [No Abstract]   [Full Text] [Related]  

  • 5. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials.
    Pepperrell T; Rodgers F; Tandon P; Sarsfield K; Pugh-Jones M; Rashid T; Keestra S
    Glob Health Action; 2021 Jan; 14(1):1892309. PubMed ID: 33627051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Learning from past mistakes? The COVID-19 vaccine and the inverse equity hypothesis.
    Todd A; Bambra C
    Eur J Public Health; 2021 Feb; 31(1):2. PubMed ID: 33393988
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintaining a Focus on Health Equity During the COVID-19 Vaccine Rollout.
    Martin EG; Birkhead GS; Holtgrave DR
    J Public Health Manag Pract; 2021 May-Jun 01; 27(3):226-228. PubMed ID: 33762538
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional vaccine production is key to ensuring equity.
    Mendis S
    BMJ; 2021 Sep; 374():n2354. PubMed ID: 34583925
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19 vaccination in incapacitated, unrepresented patients.
    Bergman J; Fero KE; Schneider PL
    J Am Geriatr Soc; 2021 Jun; 69(6):1454-1456. PubMed ID: 33742696
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 vaccine equity and booster doses.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2021 Sep; 21(9):1193. PubMed ID: 34391506
    [No Abstract]   [Full Text] [Related]  

  • 12. Canada is no global health leader on COVID-19 vaccine equity.
    Houston AR; Murthy S
    Lancet; 2021 May; 397(10287):1803. PubMed ID: 33992135
    [No Abstract]   [Full Text] [Related]  

  • 13. Could nucleocapsid be a next-generation COVID-19 vaccine candidate - author's reply.
    Oronsky B; Larson C; Caroen S; Reid TR
    Int J Infect Dis; 2022 Dec; 125():227. PubMed ID: 36347457
    [No Abstract]   [Full Text] [Related]  

  • 14. Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.
    Rubin EJ; Baden LR; Walensky RP; Morrissey S
    N Engl J Med; 2021 Apr; 384(16):e73. PubMed ID: 33882211
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
    Mehrotra DV; Janes HE; Fleming TR; Annunziato PW; Neuzil KM; Carpp LN; Benkeser D; Brown ER; Carone M; Cho I; Donnell D; Fay MP; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Juraska M; Luedtke A; Nason M; Vandebosch A; Zhou H; Cohen MS; Corey L; Hartzel J; Follmann D; Gilbert PB
    Ann Intern Med; 2021 Feb; 174(2):221-228. PubMed ID: 33090877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.
    Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R
    Int Immunopharmacol; 2021 Aug; 97():107622. PubMed ID: 33895475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccines for children in LMICs: another equity issue.
    Kampmann B; Okomo U
    Lancet; 2021 Aug; 398(10302):731-732. PubMed ID: 34339625
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Centring equity over exceptionalism in the global covid-19 response.
    Chebly KO
    BMJ; 2022 Jan; 376():o20. PubMed ID: 34992066
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 vaccines and treatments: When speed is necessary and not enough.
    Grasela TH; Price DA; Wagner JA
    Clin Transl Sci; 2021 Jul; 14(4):1201-1205. PubMed ID: 33834614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.